Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(10 years from now) | |
US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 7, 2027 |
New Chemical Entity Exclusivity (NCE) | Aug 7, 2025 |
New Patient Population (NPP) | May 27, 2025 |
NCE-1 date: August, 2024
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic